A phase I study of vaccination with NY-E
β
Kazuhiro Kakimi; Midori Isobe; Akiko Uenaka; Hisashi Wada; Eiichi Sato; Yuichiro
π
Article
π
2011
π
John Wiley and Sons
π
French
β 656 KB
## Abstract We conducted a phase I clinical trial of a cancer vaccine using a 20βmer NYβESOβ1f peptide (NYβESOβ1 91β110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 ΞΌg of NYβESOβ1f peptide mixed with 0.2 KE Picibanil OKβ432